TUMOR-DERIVED GDF-15 PREVENTS THERAPY SUCCESS OF CHECKPOINT INHIBITORS BY BLOCKING T-LYMPHOCYTE RECRUITMENT

Haake M, Schaefer T, Haack B, Vashist N, Genssler S, Harter P, Martens A, Wistuba-Hamprecht K, Wedekink F, Fischer B, Mittelbronn M, Levesque M, Cheng P, Dummer R, Weide B, Klar K, Leo E, Nimmerjahn F, Schuberth-Wagner C, Wischhusen J (2021)


Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: A597-A597

Conference Proceedings Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER

DOI: 10.1136/jitc-2021-SITC2021.568

Abstract

Immune checkpoint blockade (ICB) can achieve durable responses in a subgroup of patients with metastatic cancer, only. Poor immune effector cell infiltration into the tumor microenvironment is a major obstacle to successful therapy. Growth and differentiation factor 15 (GDF-15) is a divergent member of the TGF-β superfamily and has been linked to feto-maternal tolerance, anorexia but recently also to potent local immunosuppression under physiologic and pathophysiologic conditions. GDF-15 is overexpressed in a wide variety of tumors and may be key factor produced by tumors to prevent effective immune cell infiltration into the tumor and to potently block checkpoint inhibitor activity.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Haake, M., Schaefer, T., Haack, B., Vashist, N., Genssler, S., Harter, P.,... Wischhusen, J. (2021). TUMOR-DERIVED GDF-15 PREVENTS THERAPY SUCCESS OF CHECKPOINT INHIBITORS BY BLOCKING T-LYMPHOCYTE RECRUITMENT. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (pp. A597-A597). LONDON: BMJ PUBLISHING GROUP.

MLA:

Haake, Markus, et al. "TUMOR-DERIVED GDF-15 PREVENTS THERAPY SUCCESS OF CHECKPOINT INHIBITORS BY BLOCKING T-LYMPHOCYTE RECRUITMENT." Proceedings of the JOURNAL FOR IMMUNOTHERAPY OF CANCER LONDON: BMJ PUBLISHING GROUP, 2021. A597-A597.

BibTeX: Download